Detail
| LncRNA Name | DSCAM-AS1 |
| Synonyms | DSCAM-AS1, M41 |
| Region | GRCh38_21:40383083-40385358 Sequence |
| Ensembl | ENSG00000235123 |
| RefSeq | NR_038896 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✘ |
| MiRNA | ✘ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | RNA-seq, qPCR, RNAi, RIP, ChIP, Cell proliferation assay etc. |
| Sample | cell lines (T47D, ZR75-1, HEK293, MCF7) |
| Expression Pattern | up-regulated |
| Function Description | Among the luminal breast cancers, DSCAM-AS1 is expressed significantly higher in luminal B, a clinical subtype containing most of the clinically aggressive ER-positive breast cancers. We demonstrate that DSCAM-AS1 mediates tumour progression and tamoxifen resistance and identify hnRNPL as an interacting protein involved in the mechanism of DSCAM-AS1 action. |
| Pubmed ID | 27666543 |
| Year | 2016 |
| Title | The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. |
| External Links |
| Links for DSCAM-AS1 | GenBank HGNC lncrnadb Noncode |
| Links for breast cancer | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.